Werbung
Werbung

TMDX

TMDX logo

TransMedics Group, Inc. Common Stock

137.18
USD
Gesponsert
-0.39
-0.28%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

138.50

+1.33
+0.97%

TMDX Ergebnisberichte

Positives Überraschungsverhältnis

TMDX übertreffen die 17 der letzten 27Schätzungen.

63%

Nächster Bericht

Datum des nächsten Berichts
25. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$158.48M
/
$0.39
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+10.19%
/
-40.91%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+30.31%
/
+105.26%

TransMedics Group, Inc. Common Stock earnings per share and revenue

On 29. Okt. 2025, TMDX reported earnings of 0.66 USD per share (EPS) for Q3 25, beating the estimate of 0.35 USD, resulting in a 84.41% surprise. Revenue reached 143.82 million, compared to an expected 148.16 million, with a -2.93% difference. The market reacted with a +1.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of 0.39 USD, with revenue projected to reach 158.48 million USD, implying an decrease of -40.91% EPS, and increase of 10.19% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
For Q3 2025, TransMedics Group, Inc. Common Stock reported EPS of $0.66, beating estimates by 84.41%, and revenue of $143.82M, -2.93% below expectations.
The stock price moved up 1.09%, changed from $134.32 before the earnings release to $135.79 the day after.
The next earning report is scheduled for 25. Feb. 2026.
Based on 14 analysts, TransMedics Group, Inc. Common Stock is expected to report EPS of $0.39 and revenue of $158.48M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung